SELECT-3: a phase I study of selumetinib in combination with platinum-doublet chemotherapy for advanced NSCLC in the first-line setting

BACKGROUND: We investigated selumetinib (AZD6244, ARRY-142886), an oral, potent, and highly selective, allosteric MEK1/2 inhibitor, plus platinum-doublet chemotherapy for patients with advanced/metastatic non-small cell lung cancer. METHODS: In this Phase I, open-label study (NCT01809210), treatment...

Descripción completa

Detalles Bibliográficos
Autores principales: Greystoke, Alastair, Steele, Nicola, Arkenau, Hendrik-Tobias, Blackhall, Fiona, Md Haris, Noor, Lindsay, Colin R, Califano, Raffaele, Voskoboynik, Mark, Summers, Yvonne, So, Karen, Ghiorghiu, Dana, Dymond, Angela W, Hossack, Stuart, Plummer, Ruth, Dean, Emma
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2017
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5625674/
https://www.ncbi.nlm.nih.gov/pubmed/28950288
http://dx.doi.org/10.1038/bjc.2017.271

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5625674/
https://www.ncbi.nlm.nih.gov/pubmed/28950288
http://dx.doi.org/10.1038/bjc.2017.271

Ejemplares similares